Narrative review examines neuromodulators and brain-gut therapies for disorders of gut-brain interaction
Can therapy help your gut as much as medication? A review suggests it might
A narrative review synthesizes literature on treating disorders of gut-brain interaction (DGBI).
For gut-brain disorders, brain-gut behavior therapies like cognitive behavioral therapy can be just as effective as medication while also im…
Small pilot study finds gut microbiome differences in diarrheal versus non-diarrheal samples
Small study finds gut bacteria differences in people with and without diarrhea
A cross-sectional observational pilot study of 28 fecal samples (23 non-diarrheal, 5 diarrheal) found significant differences in gut microbi…
Gut bacteria structures differ significantly between people with and without diarrhea, with Firmicutes being the most common type found in m…
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Can an oral drug help people with fatty liver disease? Early safety study begins
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
Phase IIb trial of HH-003 injection for chronic HDV infection completes enrollment of 101 patients
Could a new antibody treatment help people with a serious liver infection?
A multicenter, randomized, controlled, open-label Phase IIb study assessed the efficacy and safety of HH-003 injection in subjects with chro…
A new antibody injection helped control a serious liver virus and heal inflammation in patients with chronic hepatitis delta infection.
Phase 1b/2 study of ERAS-007 combinations in advanced GI malignancies completes enrollment of 101 patients
Can a new drug combination help people with advanced colorectal or pancreatic cancer?
A Phase 1b/2 platform study evaluated ERAS-007 in combination with other cancer therapies in patients with advanced gastrointestinal maligna…
A new drug combination tested in advanced colorectal and pancreatic cancer aims to find safe doses and early signs of tumor shrinkage in pat…
Phase 2 trial tests metformin with neoadjuvant radiochemotherapy for locally advanced rectal cancer
Could a common diabetes drug help people with rectal cancer respond better to treatment?
A Phase 2 trial (n=60) evaluated adding metformin to neoadjuvant radiochemotherapy (capecitabine + 50 Gy radiation) for locally advanced rec…
Adding a common diabetes pill to pre-surgery treatment for rectal cancer may help clear out cancer cells before the operation begins.
Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
A phase 2 randomized controlled trial enrolled 200 adults with NAFLD to compare three doses of Vitamin E (200 IU, 400 IU, 800 IU) with place…
A completed trial on Vitamin E for fatty liver disease has finished, but the results showing if the doses helped or caused harm are not yet …
Phase 2 Trial: SHR-1701 Plus Chemoradiotherapy for Advanced Rectal Cancer
Could a new drug boost treatment for severe colorectal cancer?
A Phase 2 trial is recruiting to evaluate SHR-1701 with chemoradiotherapy in severe CRC. Primary outcome is pCR.
A new drug combined with standard chemo and radiation aims to clear severe colorectal cancer before surgery in an upcoming trial.
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now Recruiting
Could a new treatment help fight colorectal cancer more effectively?
A Phase II trial is recruiting to assess SHR-8068 with Adebrelimab and Bevacizumab in colorectal cancer for pCR and PFS.
A new drug combo for colorectal cancer is being tested in 200 patients to see if it improves survival and tumor response.
Guselkumab Shows Promise in Crohn's Disease: Phase 3 Study Results
Can a new treatment help people with Crohn's disease feel better and stay better?
The Phase 2/3 study evaluates guselkumab's efficacy and safety in Crohn's disease. Primary outcomes include changes in CDAI and clinical rem…
A new Crohn's treatment study with 1,409 participants aims to help people feel better and stay better for up to 48 weeks.
Vedolizumab with Adalimumab or Ustekinumab Studied for Crohn's Endoscopic Response
Can New Drug Combinations Offer Hope for Crohn's Disease Sufferers?
Phase 4 trial investigates vedolizumab with adalimumab or ustekinumab in Crohn's. Primary endpoint: endoscopic response at 26 weeks.
Adults with moderate to severe Crohn's disease may find new relief by combining vedolizumab with adalimumab or ustekinumab before continuing…
High Dietary Inflammatory Index Linked to Increased NAFLD Risk (OR 1.33, CI 1.23-1.44)
Could Your Diet Be Fueling Fatty Liver Disease?
Meta-analysis of 262,468 participants shows high Dietary Inflammatory Index (DII) significantly increases risk of NAFLD (OR 1.33, 95% CI: 1.…
A high-inflammation diet is strongly linked to fatty liver disease and liver scarring in a review of over 262,000 people.